

Datasheet: HCA236

Description:	HUMAN ANTI OMALIZUMAB
Specificity:	OMALIZUMAB
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD20669
Isotype:	HuCAL Fab monovalent
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

A monovalent human recombinant Fab selected from the HuCAL® phage display library, expressed in *E. coli*. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.

Preparation

Metal chelate affinity chromatography

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

IgG concentration 0.5 mg/ml

Immunogen

Omalizumab.

Specificity

Omalizumab (brand name Xolair®) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.

Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of

asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.

Human anti omalizumab, clone AbD20669 is a paratope specific anti-idiotypic (Type 1) antibody that binds specifically to omalizumab but not to free IgE or the drug/immunoglobulin complex. This antibody can be used to measure omalizumab levels in serum from patients. Clone AbD20669 is particularly suited for use as a capture reagent in Pharmacokinetic (PK) assay development.

Other Type 1 ([HCA235](#)) and Type 3 ([HCA237](#), [HCA238](#)) antibodies to omalizumab are also available from Bio-Rad in IgG1 and Fab formats. This range of anti omalizumab antibodies forms part of a wider and expanding portfolio of anti-idiotypic antibodies that have been developed for the detection of biotherapeutics.

Affinity	The monovalent intrinsic affinity of HCA236 was measured as $K_d = 1.1$ nM by real time, label free molecular interaction analysis on immobilized omalizumab
ELISA	This product may be used as a capture reagent in PK assay development together with HCA235P as the detection reagent. Protocol: PK bridging ELISA to measure free drug
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Xolair® is a registered trademark of Novartis. His-tag is a registered trademark of EMD Biosciences.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Secondary Antibodies

Mouse Anti Synthetic Peptide HISTIDINE TAG (MCA5995...) [HRP](#)

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049B\)](#)

[RECOMBINANT HUMAN IgE LAMBDA \(HCA171\)](#)

[RECOMBINANT HUMAN IgE KAPPA \(HCA190\)](#)

[HUMAN ANTI OMALIZUMAB \(HCA236\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK003P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK004P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK005P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK006P\)](#)

[RAT ANTI DYKDDDDK TAG:HRP \(MCA4764P\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

'M371662:200612'

Printed on 11 Aug 2020

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)